SCHEMBL6976531

SCHEMBL6976531

CCC(=O)Oc1c(NS(=O)(=O)c2ccc3nc(Cl)sc3c2)cccc1OCCCN1C(=O)c2ccccc2C1=O

nearest known ligand 0.42

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.42
SMN1; SMN2 Q16637 3/20 0.39
LMNA P02545 3/20 0.38
PKM P14618 1/20 0.38
MAPK1 P28482 2/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
MAPT P10636 4/20 0.38
KDM4E B2RXH2 1/20 0.36
HTT P42858 1/20 0.36
GLO1 Q04760 1/20 0.36
TP53 P04637 1/20 0.35
WDR5 P61964 1/20 0.35
MEN1 O00255 1/20 0.34
KMT2A Q03164 1/20 0.34
POLB P06746 1/20 0.34
CTSD P07339 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5756031 0.87 ALDH1A1 (0.39) ALDH1A1SMN1; SMN2LMNAMAPK1MAPT
SCHEMBL6979299 0.85 CTSD (0.42) ALDH1A1SMN1; SMN2LMNAMAPK1MAPT
SCHEMBL6976510 0.73 PPARG (0.41) SMN1; SMN2LMNAMAPK1MAPTHTT
SCHEMBL5752915 0.72 ITGB3 (0.45) ALDH1A1SMN1; SMN2MAPTMEN1KMT2A
SCHEMBL6976460 0.71 PPARA (0.42) ALDH1A1SMN1; SMN2LMNAPKMMAPT
SCHEMBL6976528 0.64 ALDH1A1 (0.42) ALDH1A1SMN1; SMN2MAPK1MAPTTP53
SCHEMBL8483991 0.63 RAB9A (0.52) ALDH1A1SMN1; SMN2LMNAMAPK1L3MBTL1
SCHEMBL22241704 0.62 SMN1; SMN2 (0.52) ALDH1A1SMN1; SMN2LMNAPKMMAPK1
SCHEMBL6977361 0.62 RAB9A (0.65) ALDH1A1SMN1; SMN2MAPTMEN1KMT2A
SCHEMBL8486911 0.61 ALDH1A1 (0.56) ALDH1A1SMN1; SMN2LMNAL3MBTL1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6548667-B2 For prevention and treatment of diseases caused by overexpression and overactivation of matrix metalloproteinase SAMSUNG ELECTRONICS CO. LTD. (KR) 2003-04-15 US disclosed
EP-1208092-A4 SULFONAMIDE DERIVATIVE AS A MATRIX METALLOPROTEINASE INHIBITOR SAMSUNG ELECTRONICS CO LTD (KR) 2003-01-02 EP disclosed
US-20020169314-A1 Sulfonamide derivative as a matrix metalloproteinase inhibitor SAMSUNG ELECTRONICS CO. LTD. (KR) 2002-11-14 US disclosed
EP-1208092-A1 SULFONAMIDE DERIVATIVE AS A MATRIX METALLOPROTEINASE INHIBITOR SAMSUNG ELECTRONICS CO., LTD. (KR) 2002-05-29 EP disclosed
WO-2001077092-A1 SULFONAMIDE DERIVATIVE AS A MATRIX METALLOPROTEINASE INHIBITOR SAMSUNG ELECTRONICS CO., LTD. (KR) 2001-10-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020169314-A1 Sulfonamide derivative as a matrix metalloproteinase inhibitor MMP9, MMP3, MMP14 ALDH1A1 311/4885SMN1; SMN2 654/4885LMNA 1839/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.